ETOPOSIDE, DOXORUBICIN, CYCLOPHOSPHAMIDE, PREDNISONE, ADCETRIS 50 mg powder for concentrate for solution for infusion clinical trials

A Phase II Open Label Study of Brentuximab Vedotin in Combination with CHEP in Patients with Previously Untreated CD30-expressing Peripheral T-cell Lymphomas (PTCL)

This study is looking at a new combination of medicines, including Brentuximab Vedotin (Adcetris), for adults with a type of cancer called CD30-expressing Peripheral T-cell Lymphoma (PTCL) that hasn't been treated before. We want to see how well this new treatment shrinks the cancer.